

Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images

Abhinav Sharma¹, Sandy Kang Lövgren^{1,5}, Kajsa Ledesma Eriksson^{1,5}, Yinxi Wang^{1,5},
Stephanie Robertson^{2,5}, Johan Hartman^{2,3,4}, Mattias Rantalainen^{1,4}

Corresponding author: Mattias Rantalainen

Email: mattias.rantalainen@ki.se

Table of content:

Table 1. Baseline characteristics of the cohorts from two different hospitals in Sweden.

Table 1: Baseline characteristics of the cohorts from two different hospitals in Sweden.

	CHIME breast KS Solna (N=1670)	SCAN-B (N=1049)	Overall (N=2719)
Age			
Mean (SD)	61.3 (12.4)	65.1 (12.4)	62.8 (12.5)
Median [Min, Max]	63.0 [29.0, 94.0]	65.0 [30.0, 95.0]	65.0 [29.0, 95.0]
Tumor_size			
<20mm	1124 (67.3%)	707 (67.4%)	1831 (67.3%)
>=20mm	533 (31.9%)	332 (31.6%)	865 (31.8%)
Missing	13 (0.8%)	10 (1.0%)	23 (0.8%)
Lymph_node			
Negative	1185 (71.0%)	719 (68.5%)	1904 (70.0%)
Positive	344 (20.6%)	298 (28.4%)	642 (23.6%)
Missing	141 (8.4%)	32 (3.1%)	173 (6.4%)
NHG			
1	361 (21.6%)	221 (21.1%)	582 (21.4%)
2	879 (52.6%)	513 (48.9%)	1392 (51.2%)
3	430 (25.7%)	315 (30.0%)	745 (27.4%)
ER_status			
Negative	193 (11.6%)	109 (10.4%)	302 (11.1%)
Positive	1470 (88.0%)	937 (89.3%)	2407 (88.5%)
Missing	7 (0.4%)	3 (0.3%)	10 (0.4%)
HER2_status			
Negative	1462 (87.5%)	946 (90.2%)	2408 (88.6%)
Positive	167 (10.0%)	88 (8.4%)	255 (9.4%)
Missing	41 (2.5%)	15 (1.4%)	56 (2.1%)
PFS_in_years			
Mean (SD)	6.32 (2.52)	5.34 (2.27)	5.94 (2.47)
Median [Min, Max]	6.51 [0.153, 10.8]	5.31 [0.115, 10.2]	6.15 [0.115, 10.8]
PFS_status			

0	1580 (94.6%)	1013 (96.6%)	2593 (95.4%)
1	90 (5.4%)	36 (3.4%)	126 (4.6%)

NHG=Nottingham histological grade, ER=oestrogen receptor, HER2=human epidermal growth factor receptor 2, PFS=Progression-free survival.